undamentalytics Newsletter
Sign in

Geovax Labs, Inc. (GOVX) stock

Add to watchlist

Add holding +

NASDAQ: GOVX Nasdaq Biotechnology Next results ~November 12, 2026

E Fundamentals grade

Geovax Labs, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

Not valued: the figures our models need are missing or failed our data-quality checks.

Price vs value

No model value: cash-flow, stock-pay or share-count figures missing or out of date. How we value companies.

Geovax Labs, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds7 adding, 9 cuttingOf 1 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Geovax Labs files

Where Geovax Labs stands after its latest 10-Q

Geovax Labs has little or no product revenue yet; it used $18m of cash in the twelve months to June 2026. That puts it 118 of 122 for growth among the biotechnology companies we cover. Against its peers on growth, profitability, cash generation and balance sheet, it grades E. It passes 2 of our 2 financial-health checks.

Our models give no value for Geovax Labs at present, so past values are not shown.

Source: 10-Q filed July 27, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Geovax Labs, Inc.'s trailing-twelve-month revenue fell 100.0% year on year, with a free-cash-flow margin of -2236.0%. Where it lags: revenue growth of -100.0% ranks 167 of 172 biotechnology companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to -100.0% (-15.2pp vs the prior quarter), the 4th consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Geovax Labs, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 12 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 100.0% over the last 12 months.
  • Growth slowing. The growth rate is 15.2 points lower than a quarter earlier.
  • Loss-making. Operating margin is -2523.4%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 2082.3 points on a year ago.
  • Burning cash. Free cash flow was -2236.0% of revenue over the last 12 months.

Latest results: FY2026 Q2

Filed July 27, 2026
Earnings per share
-$0.97 against an average estimate of -$2.15: beat by 55.0%
Share reaction
-0.5% in the first session after the results on July 27, 2026, against +0.3% for the S&P 500

Geovax Labs' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-3.6%
  • 1 week-16.0%
  • 1 month-49.1%
  • This year-96.2%
  • 1 year-98.8%
  • 5 years-100.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$0
Operating margin
-2523.4%
Net margin
-2507.3%

Growth

Revenue growth
−100.0%
Change in growth rate
−15.2 pts

Cash

Free cash flow (TTM)
-$18.4M
FCF margin
-2236.0%
Stock pay % of revenue
122.2%

Earnings

Last results
July 27, 2026
Next results (est.)
November 12, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Shareholder vote
  2. Leadership
  3. Announcement
  4. Agreement
  5. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Geovax Labs, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: cash-flow, stock-pay or share-count figures missing or out of date.

Valuation models

We value Geovax Labs, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 11.5%: the 10-year Treasury yield (4.9%) plus a beta of 1.46 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no positive revenue in the latest twelve months
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Geovax Labs, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202020212022202320242025
Share price$1267.50$1357.50$236.25$135.38$61.75$4.28
Market value$14.0bn$66m$32m$30m$13m$4m
+ Net debt (− = net cash)−$10m−$11m−$28m−$6m−$6m−$3m
Enterprise value$14.0bn$55m$4m$23m$7m$1m
Multiples
Price / sales n/m171.8xn/m—3.2x1.6x
Price / earnings ——————
Price / free cash flow ——————
EV / EBITDA ——————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

8 /100

Weak moat

How hard Geovax Labs's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -344.5% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -353.6%; its worst year was -17207.5%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 5 years, at a median -2236.0% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 108.4% over five years; stock-based pay has been a median 28.8% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$5.14 +77% — −100%
Next −$2.85 +45% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −40.9% on 90 days ago. In the last 30 days, 0 analysts raised Geovax Labs, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Geovax Labs, Inc., last 90 days
−$10.00 −$5.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$8.70 Current fiscal year, 60 days ago: −$8.70 Current fiscal year, 30 days ago: −$5.14 Current fiscal year, 7 days ago: −$5.14 Current fiscal year, Now: −$5.14 −$5.14 Next fiscal year, 90 days ago: −$3.07 Next fiscal year, 60 days ago: −$3.07 Next fiscal year, 30 days ago: −$2.85 Next fiscal year, 7 days ago: −$2.85 Next fiscal year, Now: −$2.85 −$2.85

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$8.70−$3.07
60 days ago −$8.70−$3.07
30 days ago −$5.14−$2.85
7 days ago −$5.14−$2.85
Now −$5.14−$2.85

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$2.15 −$0.97 +55.0%
Mar 2026 −$0.84 −$2.62 −210.1%
Sept 2025 −$6.63 −$7.75 −17.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, July 27, 2026

No numeric guidance in Geovax Labs, Inc.'s latest earnings release (filed July 27, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

2 analysts, Oct 2026
Buy2100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202622
  2. Sep 202622

Counts of recommendations published by analysts covering Geovax Labs, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
2.7%
of tradable shares
Days to cover
0.32
at average volume
Short interest, 1 month
−46%
to October 15, 2026
Held by institutions
10%
of shares
Held by insiders
0.0%
of shares
Employees
19
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
GOVX+7%−83%−43%−54%−93%−96%
Industry peers (median)−36%−56%−17%−28%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
GOVX33%17%33%33%25%9%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
GOVX−58%−86%−73%−80%−94%−97%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since September 25, 2020: 100% from February 17, 2021 to November 2, 2026. Getting back needed a 1941618% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.16 – $14.35
From 52-week high
−98.9%
vs 50-day average
−55.9%
vs 200-day average
−86.9%
Volatility (1 year)
140%
Beta vs S&P 500
1.80

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±6.8%
After a week
3 up, 9 down
typical move ±24.8%
After a month
3 up, 9 down
typical move ±25.0%
Results releasedNext dayS&P 500 next day5 days21 days
July 27, 2026 −0.5% +0.3% −0.8% −12.2%
May 14, 2026 −5.4% −0.4% +111.5% −9.2%
April 15, 2026 −8.2% +1.0% −12.7% −6.0%
November 13, 2025 −9.4% −1.7% −19.5% −33.1%
July 29, 2025 +3.4% −0.4% −1.5% +2.4%
May 1, 2025 0.0% +2.2% −4.0% +3.0%
March 28, 2025 −16.5% −1.4% −19.7% −21.3%
November 13, 2024 −19.7% −0.6% −19.7% −27.7%
August 7, 2024 +3.9% +1.6% +80.6% +90.0%
May 15, 2024 +2.4% +1.0% +10.0% −29.4%
March 1, 2024 −8.2% +0.8% −16.8% −25.0%
November 9, 2023 −3.5% +0.8% −0.5% −41.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Geovax Labs, Inc.
$0 $2M $4M $6M $8M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $0 Revenue (TTM), FY23 Q4: $0 Revenue (TTM), FY24 Q1: $0 Revenue (TTM), FY24 Q2: $300.7K Revenue (TTM), FY24 Q3: $3.1M Revenue (TTM), FY24 Q4: $4M Revenue (TTM), FY25 Q1: $5.6M Revenue (TTM), FY25 Q2: $6.1M Revenue (TTM), FY25 Q3: $3.4M Revenue (TTM), FY25 Q4: $2.5M Revenue (TTM), FY26 Q1: $852.3K Revenue (TTM), FY26 Q2: $0 $0

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $0
FY23 Q4 $0
FY24 Q1 $0
FY24 Q2 $300.7K
FY24 Q3 $3.1M
FY24 Q4 $4M
FY25 Q1 $5.6M
FY25 Q2 $6.1M
FY25 Q3 $3.4M
FY25 Q4 $2.5M
FY26 Q1 $852.3K
FY26 Q2 $0
Revenue growth, TTM YoY Geovax Labs, Inc.
-1000% 0% 1000% 2000% FY22 Q2 FY23 Q1 FY23 Q4 FY26 Q2 Revenue growth, TTM YoY, FY22 Q2: -67.7% Revenue growth, TTM YoY, FY22 Q3: -47.8% Revenue growth, TTM YoY, FY22 Q4: -78.9% Revenue growth, TTM YoY, FY23 Q1: -100.0% Revenue growth, TTM YoY, FY23 Q2: -100.0% Revenue growth, TTM YoY, FY23 Q3: -100.0% Revenue growth, TTM YoY, FY23 Q4: -100.0% Revenue growth, TTM YoY, FY25 Q2: 1943.1% Revenue growth, TTM YoY, FY25 Q3: 8.5% Revenue growth, TTM YoY, FY25 Q4: -37.1% Revenue growth, TTM YoY, FY26 Q1: -84.8% Revenue growth, TTM YoY, FY26 Q2: -100.0% -100.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY22 Q2 -67.7%
FY22 Q3 -47.8%
FY22 Q4 -78.9%
FY23 Q1 -100.0%
FY23 Q2 -100.0%
FY23 Q3 -100.0%
FY23 Q4 -100.0%
FY25 Q2 1943.1%
FY25 Q3 8.5%
FY25 Q4 -37.1%
FY26 Q1 -84.8%
FY26 Q2 -100.0%
Operating margin (TTM) Geovax Labs, Inc.
-20000% -15000% -10000% -5000% 0% FY22 Q1 FY22 Q4 FY24 Q4 FY26 Q1 Operating margin (TTM), FY22 Q1: -5498.9% Operating margin (TTM), FY22 Q2: -7354.8% Operating margin (TTM), FY22 Q3: -9081.5% Operating margin (TTM), FY22 Q4: -17207.5% Operating margin (TTM), FY24 Q2: -9059.2% Operating margin (TTM), FY24 Q3: -792.6% Operating margin (TTM), FY24 Q4: -635.8% Operating margin (TTM), FY25 Q1: -441.1% Operating margin (TTM), FY25 Q2: -407.3% Operating margin (TTM), FY25 Q3: -761.6% Operating margin (TTM), FY25 Q4: -869.3% Operating margin (TTM), FY26 Q1: -2523.4% -2523.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY22 Q1 -5498.9%
FY22 Q2 -7354.8%
FY22 Q3 -9081.5%
FY22 Q4 -17207.5%
FY24 Q2 -9059.2%
FY24 Q3 -792.6%
FY24 Q4 -635.8%
FY25 Q1 -441.1%
FY25 Q2 -407.3%
FY25 Q3 -761.6%
FY25 Q4 -869.3%
FY26 Q1 -2523.4%
FCF margin (TTM) Geovax Labs, Inc.
-30000% -20000% -10000% 0% FY22 Q1 FY22 Q4 FY24 Q4 FY26 Q1 FCF margin (TTM), FY22 Q1: -3931.1% FCF margin (TTM), FY22 Q2: -5992.7% FCF margin (TTM), FY22 Q3: -7620.4% FCF margin (TTM), FY22 Q4: -23507.2% FCF margin (TTM), FY24 Q2: -7657.2% FCF margin (TTM), FY24 Q3: -881.5% FCF margin (TTM), FY24 Q4: -624.5% FCF margin (TTM), FY25 Q1: -447.0% FCF margin (TTM), FY25 Q2: -446.0% FCF margin (TTM), FY25 Q3: -724.4% FCF margin (TTM), FY25 Q4: -863.8% FCF margin (TTM), FY26 Q1: -2236.0% -2236.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY22 Q1 -3931.1%
FY22 Q2 -5992.7%
FY22 Q3 -7620.4%
FY22 Q4 -23507.2%
FY24 Q2 -7657.2%
FY24 Q3 -881.5%
FY24 Q4 -624.5%
FY25 Q1 -447.0%
FY25 Q2 -446.0%
FY25 Q3 -724.4%
FY25 Q4 -863.8%
FY26 Q1 -2236.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 1 1 1 1 2 0 0 0 4 2 0
EBITDA −3 −2 −3 −2 −3 −19 −14 −27 −25 −22 −20
Operating income −3 −2 −3 −2 −3 −19 −14 −27 −25 −22 −21
Net income −3 −2 −3 −2 −3 −19 −14 −26 −25 −21 −20
Diluted EPS −$0.40 −$3.75 −$1951291.25 −$97733.75 −$267.50 −$15.20 — — — — —
Growth (year on year)
Revenue — +29.7% −10.4% +22.1% +55.1% −78.9% −78.9% −100.0% — −37.1% −100.0%
Margins
EBITDA margin −391.4% −199.6% −264.0% −201.1% −153.4% <−999% <−999% — −633.4% −866.6% —
Operating margin −394.9% −202.2% −266.1% −201.8% −154.5% <−999% <−999% — −635.8% −869.3% —
Net margin −394.7% −201.8% −265.8% −201.6% −162.2% <−999% <−999% — −632.0% −862.3% —
Free-cash-flow margin — −157.4% — −119.6% −159.4% <−999% <−999% — −624.5% −863.8% —
Cash flow
Cash from operations −2 −2 −2 −1 −3 −11 −19 −25 −25 −21 −18
Capital spending — 0 — 0 0 0 0 0 0 0 0
Free cash flow — −2 — −1 −3 −11 −19 −25 −25 −22 −18
Stock-based pay 1 0 0 0 0 0 1 1 1 1 1
Free cash flow after stock pay — −2 — −2 −3 −12 −20 −26 −25 −23 −19
Balance sheet
Cash 0 0 0 0 10 11 28 6 6 3 3
Total debt 0 0 0 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −0 −0 0 −0 −10 −11 −28 −6 −6 −3 −3
Diluted shares — — — — 11m — — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $5m
Short-term assets $4mLonger-term assets $0m
What it owes, and who funded it · $5m
Short-term liabilities $3mLonger-term liabilities $0mShareholders' equity $2m
  • Short-term assets cover short-term liabilities $4m of assets due within a year against $3m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $4m short-term assets against $169,568 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Geovax Labs, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
1956.0%
of revenue

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth -100.0% 12.6% 167 of 172
Change in growth rate Growth -15.2pp -0.1pp 122 of 172
Operating margin Profitability -2523.4% -189.4% 149 of 175
Net margin Profitability -2507.3% -157.3% 154 of 180
Free-cash-flow margin Cash generation -2236.0% -145.4% 152 of 176
Stock pay as % of revenue Cash generation 122.2% 19.2% 140 of 179

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$625,500
Institutions reporting
16
Shares held vs prior quarter
▲ 47.9%
Positions opened / closed
5 / 4

Top buyers and sellers, Q2 2026: 7 institutions bought and 9 sold ; the biggest buyer was Jane Street Group, LLC (+315K shares) and the biggest seller Armistice Capital, LLC (−269K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Jane Street Group, LLC $400,399 315K 64.0% New
HRT Financial LP $160,000 127K 25.6% New
Geode Capital Management, LLC $26,811 21K 4.3% ▼ 41.5%
Two Sigma Securities, LLC $13,566 11K 2.2% New
Vanguard Fiduciary Trust Co $6,436 5K 1.0% 0.0%
Tower Research Capital LLC (TRC) $4,448 4K 0.7% ▼ 0.7%
Vanguard Capital Management LLC $4,086 3K 0.7% 0.0%
Sbi Securities Co., Ltd. $3,287 3K 0.5% ▲ 574.0%
Morgan Stanley $2,544 2K 0.4% ▲ 33283.3%
Jones Financial Companies LLLP $1,320 1K 0.2% New
UBS Group AG $1,199 1K 0.2% ▼ 77.8%
Blackrock, Inc. $1,069 1K 0.2% ▼ 23.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Geovax Labs, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 12, 2026 estimated from the company's past filing pattern, not announced

  • July 27, 2026
  • May 14, 2026
  • April 15, 2026
  • November 13, 2025
  • July 29, 2025
  • May 1, 2025

Recent SEC filings

Data status

When each part of this page on Geovax Labs, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Geovax Labs, Inc. in brief

What does Geovax Labs, Inc. do?
Geovax Labs, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Geovax Labs, Inc.'s stock ticker?
Geovax Labs, Inc. trades under the ticker GOVX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Geovax Labs, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Geovax Labs, Inc. reported revenue of $0, 100.0% lower than a year earlier, according to its SEC filings.
What is Geovax Labs, Inc.'s free cash flow?
Geovax Labs, Inc.'s free-cash-flow margin is -2236.0% of revenue over the trailing twelve months, ranking 152 of the 176 biotechnology companies we cover.
Who are Geovax Labs, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Jane Street Group, LLC, HRT Financial LP and Geode Capital Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Geovax Labs, Inc.'s market cap?
On December 31, 2025, Geovax Labs, Inc.'s market capitalisation was about $4.1M and net debt of -$3.1M. Market figures come from third-party market data and may be delayed.
When is Geovax Labs, Inc.'s next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Geovax Labs, Inc. announces its own schedule.